Induction therapy for advanced-stage hodgkin lymphoma: Late intensification (abvd chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant only for those who relapse)

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

The goal of therapy for patients with advanced-stage Hodgkin lymphoma is to ensure that as many patients as possible are healthy and free of disease decades after completing treatment. To achieve this, the treating physician needs to select the most effective therapeutic regimen, but also needs to choose a treatment strategy that limits long-term toxicity. One approach to achieve this is to use a less intense combination, such as ABVD chemotherapy, as initial treatment and intensify therapy only in those patients who do not become PET negative or who subsequently relapse.

Original languageEnglish (US)
Pages (from-to)75-86
Number of pages12
JournalHematology/Oncology Clinics of North America
Volume28
Issue number1
DOIs
StatePublished - Feb 1 2014

Keywords

  • ABVD chemotherapy
  • Escalated BEACOPP
  • Event-free survival (EFS)
  • Failure-free survival (FFS)
  • Hodgkin lymphoma
  • Overall survival (OS)
  • Response rate
  • Toxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Induction therapy for advanced-stage hodgkin lymphoma: Late intensification (abvd chemotherapy followed by high-dose chemotherapy and autologous stem cell transplant only for those who relapse)'. Together they form a unique fingerprint.

  • Cite this